MustGrow Biologics Corp (MGRO)

MustGrow Closes $3.7 Million Non-Brokered LIFE OfferingJune 19, 2026 5:00 PM
NewsfileSaskatoon, Saskatchewan--(Newsfile Corp. - June 19, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the closing of its previously announced non-brokered private placement of 7,481,541 units of the Company (each, a "Unit") at a price of $0.50 per Unit for gross proceeds of approximately $3,741,000 (the "LIFE Offering"). Each Unit consists of (i) one common share of the Company (each, a "Common Share") and (ii) one common share purchase warrant (each, a "Warrant"). Each whole Warrant will be exercisable for a period of 60 months from the date of closing and will entitle the holder thereof to purchase one additional Common Share (each, a "Warrant Share") at an exercise price of $0.70 per Warrant Share. The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSanteTM and working capital and general corporate purposes.The Units sold pursuant to the LIFE Offering were offered in Canada pursuant to the listed issuer financing exemption from the prospectus requirement available under Part 5A of National Instrument 45-106 - Prospectus Exemptions as modified by Coordinated Blanket Order 45-935 Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933 (the "1933 Act"), as amended, and in certain other jurisdictions outside of Canada and the United States provided that no prospectus filing or comparable obligation arises in such other jurisdiction. Subject to the rules and policies of the TSX Venture Exchange (the "TSXV"), the securities issuable from the sale of Units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws. The LIFE Offering remains subject to final approval of the TSXV.As consideration for services, certain eligible finders received: (i) an aggregate cash fee equal to $110,865, being 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by such finders; and (ii) 221,730 non-transferable Common Share purchase warrants (the "Finder's Warrants"), being 6.0% of the aggregate number of Units sold to investors introduced to the Company by the finder. Each Finder's Warrant entitles its holder to purchase one Common Share (a "Finder Warrant Share") at a price of $0.70 per Finder Warrant Share for a 60-month period. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof are subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws.This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the 1933 Act, or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.About MustGrowMustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSanteTM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 108 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 70.4 million common shares issued and outstanding, and approximately 91.9 million shares on a fully diluted basis.For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about the intended use of proceeds of the LIFE Offering, and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: risks relating to the Company's receipt of final TSVV approval of LIFE Offering on the terms contemplated herein, or at all, and those risks described in more detail in MustGrow's annual information form for the year ended December 31, 2025 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.© 2026 MustGrow Biologics Corp. All rights reserved.THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/302247 Original: MustGrow Closes $3.7 Million Non-Brokered LIFE Offering

MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 MillionJune 17, 2026 7:21 PM
NewsfileTHIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESSaskatoon, Saskatchewan--(Newsfile Corp. - June 17, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTC: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce that, in connection with its previously announced non-brokered private placement of units (each, a "Unit") at a price of $0.50 per Unit, and as a result of strong investor demand, the Company intends to proceed with closing tomorrow, June 18, 2026, by issuing approximately 7.4 million Units, for aggregate gross proceeds to the Company of approximately $3.7 million (the "LIFE Offering").Each Unit will consist of: (i) one common share in the capital of the Company (each, a "Common Share"); and (ii) one Common Share purchase warrant (each, a "Warrant"). Each Warrant will be exercisable for a period of 60 months from the Closing Date (defined below) and will entitle the holder thereof to purchase one additional Common Share (each, a "Warrant Share") at an exercise price of $0.70 per Warrant Share.The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSanteTM and working capital and general corporate purposes.Subject to the rules and policies of the TSX Venture Exchange (the "TSXV"), the securities issuable from the sale of Units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws. Insiders and certain consultants that participate in the LIFE Offering would be subject to a four-month hold period pursuant to applicable policies of the TSXV.There is an offering document related to the LIFE Offering that can be accessed under the Company's profile at www.sedarplus.ca and on the Company's website at www.MustGrow.ca. Prospective investors should read this offering document before making an investment decision.The Units sold pursuant to the LIFE Offering will be offered in Canada pursuant to the listed issuer financing exemption from the prospectus requirement available under Part 5A of National Instrument 45-106 - Prospectus Exemptions as modified by Coordinated Blanket Order 45-935 Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933 (the "1933 Act"), as amended, and in certain other jurisdictions outside of Canada and the United States provided that no prospectus filing or comparable obligation arises in such other jurisdiction. Closing of the LIFE Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals, including the approval of the TSXV.As consideration for services, certain eligible finders may receive: (i) an aggregate cash fee equal up to 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by the finder; and (ii) non-transferable Common Share purchase warrants (the "Finder's Warrants") representing up to 6.0% of the aggregate number of Units sold to investors introduced to the Company by the finder. Each Finder's Warrant will entitle its holder to purchase one Common Share (a "Finder Warrant Share") at a price of $0.70 per Finder Warrant Share for a 60-month period. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws.Not an Offer to Sell or Solicitation in the USThis news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the 1933 Act, or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.About MustGrowMustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSanteTM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 108 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 63.0 million common shares issued and outstanding, and approximately 76.7 million shares on a fully diluted basis.For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about: the LIFE Offering, the intended closing date of the LIFE Offering and if the LIFE Offering closes at all, the intended use of proceeds, and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: risks relating to the Company's ability to complete the proposed LIFE Offering on the terms and timeline contemplated herein, or at all, including the receipt of conditional and final approvals from the TSXV and satisfaction of other closing conditions, and those risks described in more detail in MustGrow's annual information form for the year ended December 31, 2025 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.© 2026 MustGrow Biologics Corp. All rights reserved.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301992 Original: MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million

MustGrow Announces First Quarter 2026 Financial ResultsMay 28, 2026 5:00 PM
NewsfileInvestor Webcast: Friday, May 29th at 4:00pm ET / 1:00pm PT
Register/View Here: https://us02web.zoom.us/webinar/register/7717781882447/WN_m6cQAgeQSD6hjP6JeVpfbw
Please join/register at least 5 minutes prior to the call. Email questions before 2:00pm ET to info@mustgrow.ca, which will be addressed during the Q&A portion of the webcast.Saskatoon, Saskatchewan--(Newsfile Corp. - May 28, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended March 31, 2026. For complete details, please refer to the condensed interim financial statements for the three months ended March 31, 2026, and associated management's discussion and analysis, available on the Company's profile at SEDAR+: www.sedarplus.ca or on the Company's website at: www.mustgrow.ca.Key Highlights for Q1-2026:TerraSante sales revenue of $0.1 million in Q1-2026 vs. nil in Q1-2025TerraSante gross margin of 23.6% in Q1-2026, up from 19.5% in 20251Expenses from continuing operations2 of $0.9 million in Q1-2026, down from $1.2 million in Q1-2025Net loss of $1.3 million in Q1-2026, down from $1.6 million in Q1-2025Cash and equivalents on hand as at March 31, 2026 was $0.4 million, with working capital of $1.5 million"During the first quarter, our TerraSante™ contract manufacturers were increasing production capacity to accommodate our forward-looking product requirements, resulting in short-term manufacturing disruptions as production expanded from 'batch' production to 'continuous' lines dedicated to produce at higher volume rates," commented Corey Giasson, President and CEO of MustGrow. "These manufacturing disruptions have carried over to the second quarter, however, despite these disruptions, as production capacity for our products increases with our contract manufacturers, so will our ability to execute on timely delivery to meet the demand for our products in the U.S."Notes:Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company's results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.Operations related to NexusBioAg are presented as discontinued operations.About MustGrowMustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSante™, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 108 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 63.0 million common shares issued and outstanding, and approximately 76.7 million shares on a fully diluted basis.For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about: achievement of increased production capacity for the Company's products by its contract manufacturers, and timing thereof; and future demand for the Company's products, and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2025 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSX Venture Exchange, nor their Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.© 2026 MustGrow Biologics Corp. All rights reserved.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299314 Original: MustGrow Announces First Quarter 2026 Financial Results

MustGrow Announces Non-Brokered LIFE Offering of Approximately $2 MillionMay 25, 2026 6:00 PM
NewsfileSaskatoon, Saskatchewan--(Newsfile Corp. - May 25, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a non-brokered private placement of units (each, a "Unit") at a price of $0.50 per Unit for aggregate gross proceeds to the Company of approximately $2,000,000 (the "LIFE Offering"). The Company reserves the right to increase the size of the Offering, as further described in the offering document.Each Unit will consist of: (i) one common share in the capital of the Company (each, a "Common Share"); and (ii) one Common Share purchase warrant (each, a "Warrant"). Each Warrant will be exercisable for a period of 60 months from the Closing Date (defined below) and will entitle the holder thereof to purchase one additional Common Share (each, a "Warrant Share") at an exercise price of $0.70 per Warrant Share.The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSanteTM and working capital and general corporate purposes.Subject to the rules and policies of the TSX Venture Exchange (the "TSXV"), the securities issuable from the sale of Units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws. Insiders and certain consultants that participate in the LIFE Offering would be subject to a four-month hold period pursuant to applicable policies of the TSXV.There is an offering document related to the LIFE Offering that can be accessed under the Company's profile at www.sedarplus.ca and on the Company's website at www.MustGrow.ca. Prospective investors should read this offering document before making an investment decision.It is expected that closing of the LIFE Offering will take place on or about June 11, 2026 or such other date(s) as may be determined the Company (the "Closing Date"). Closing of the LIFE Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals, including the approval of the TSXV.The Units sold pursuant to the LIFE Offering will be offered in Canada pursuant to the listed issuer financing exemption from the prospectus requirement available under Part 5A of National Instrument 45-106 - Prospectus Exemptions as modified by Coordinated Blanket Order 45-935 Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933 (the "1933 Act"), as amended, and in certain other jurisdictions outside of Canada and the United States provided that no prospectus filing or comparable obligation arises in such other jurisdiction.As consideration for services, certain eligible finders may receive: (i) an aggregate cash fee equal up to 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by the finder; and (ii) non-transferable Common Share purchase warrants (the "Finder's Warrants") representing up to 6.0% of the aggregate number of Units sold to investors introduced to the Company by the finder. Each Finder's Warrant will entitle its holder to purchase one Common Share (a "Finder Warrant Share") at a price of $0.70 per Finder Warrant Share for a 60-month period. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws.MI 61-101 ComplianceIt is anticipated that insiders of the Company may participate in the LIFE Offering, and any Units issued to insiders will be subject to a four month hold period pursuant to applicable policies of the TSXV. The issuance of Units to any insiders will be considered a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). In respect of any such insider participation, the Company expects to rely on exemptions from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a), as the fair market value of the transaction, insofar as it involves interested parties, does not exceed 25% of the Company's market capitalization.Not an Offer to Sell or Solicitation in the USThis news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the 1933 Act, or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.About MustGrowMustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSanteTM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 108 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 63.0 million common shares issued and outstanding, and approximately 76.7 million shares on a fully diluted basis.For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about: the LIFE Offering, the intended closing date of the LIFE Offering and if the LIFE Offering closes at all, the intended use of proceeds, and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: risks relating to the Company's ability to complete the proposed LIFE Offering on the terms and timeline contemplated herein, or at all, including the receipt of conditional and final approvals from the TSXV and satisfaction of other closing conditions, and those risks described in more detail in MustGrow's annual information form for the year ended December 31, 2025 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES© 2026 MustGrow Biologics Corp. All rights reserved.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298792 Original: MustGrow Announces Non-Brokered LIFE Offering of Approximately $2 Million

MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility ProductMay 25, 2026 7:00 AM
NewsfileMustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSanteTM.Based on infield grower data, the mustard-derived TerraSanteTM biofertility product has been shown to improve crop yields, soil, and potentially the soil microbiome health for nutrient/water use efficiencies.Saskatoon, Saskatchewan--(Newsfile Corp. - May 25, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce registration approvals from the Texas Department of Agriculture, the Utah Department of Agriculture and Food, and the Montana Department of Agriculture for its mustard plant-based TerraSanteTM, an organic biofertility product. The organic certifications are included under MustGrow's existing Organic OMRI Listed® certifications in Georgia, Florida, Arizona, Idaho, Oregon, and Washington State. The high-value crop acres grown in Texas, in particular, are a natural fit for TerraSanteTM. In 2025 for example, Texas agriculture production value included: US$108 million in melons, US$104 million in potatoes, US$85 million in pecans, and US$59 million in grapefruits, which may or may not have a direct impact on MustGrow and its business.(1) TerraSanteTM for Soil and Ecological HealthMustGrow's mustard-derived TerraSanteTM organic biofertilizer is a wettable powder containing nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and long-term sustainable soil health. TerraSanteTM is currently registered, approved and available for sale in California, Florida, Georgia, Texas, Utah, Montana, Arizona, Idaho, Oregon, and Washington State, under Organic OMRI Listed® certification and California's Organic Input Material (OIM) Program.MustGrow's biofertility program focuses on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer's most valuable asset, and MustGrow's mustard plant-based technologies are being applied with the intention to improve the health of the soil and soil microbiome, and have a positive impact on root and plant health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSanteTM has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing.To learn more about TerraSanteTM, visit TerraSanteTM - MustGrow.Sources:
1) USDA/NASS 2025 State Agriculture Overview for TexasAbout MustGrowMustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSanteTM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 108 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 63.0 million common shares issued and outstanding, and approximately 76.7 million shares on a fully diluted basis.For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about: the Company's products; 2025 aggregate Texas agriculture production values and its potential impact on the Company, if any; the impact of the Company's products on crop yields and soil health; and the future expansion plans of the Company, and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: reliance of government approvals for certain products and those risks described in more detail in MustGrow's annual information form for the year ended December 31, 2025 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on MustGrow's issuer profile on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSX Venture Exchange, nor their Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.© 2026 MustGrow Biologics Corp. All rights reserved.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298582 Original: MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility Product

MustGrow Announces 2025 Financial ResultsApril 29, 2026 5:00 PM
NewsfileInvestor Webcast: Thursday, April 30th at 4:00pm ET / 1:00pm PT
Register/View Here: https://us02web.zoom.us/webinar/register/3117774401744/WN_eXcymymWSnicArxMPOiZVA
Please join/register at least 5 minutes prior to the call.
Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.Saskatoon, Saskatchewan--(Newsfile Corp. - April 29, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative agriculture solutions, announces its audited financial results for the year ended December 31, 2025. For complete details, please refer to the Audited 2025 Financial Statements and associated Management's Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company's website: www.mustgrow.ca.Key Highlights for 2025:Sales revenue of $8.3 million in 2025 vs. $0.4 million in 2024Expenses of $7.7M in 2025, up from $5.4M in 2024, which was mostly due to the cost of running the NexusBioAg Canadian sales divisionNet losses of $7.3M in 2025, up from $4.9M in 2024TerraSanteTM biofertility sales in the U.S. were $0.6 million in 2025, up 377% from 2024 when U.S. sales were just over $0.1 million, with a gross margin of 20%1Cash and equivalents on hand as at December 31, 2025 was $0.9 million with inventory of $2.0 millionSubsequently, MustGrow raised $2 million via equity new issue in January 2026Subsequently, MustGrow closed its NexusBioAg Canadian distribution division in April 2026 to focus on TerraSante™ sales growth in the U.S."Throughout 2025, management focused on securing capital and increasing third-party manufacturing capacity to prepare for growing TerraSanteTM demand in the U.S," stated Corey Giasson, President and CEO of MustGrow. "Closing down our NexusBioAg Canadian sales division to allocate more capital and resources to TerraSanteTM production was a key strategic decision we made in 2026. TerraSanteTM sales were up 377% in 2025 versus 2024, as demand from U.S. retailers and farmers outstripped our inventory supply. For 2026, we anticipate continued growth in TerraSanteTM sales and an improvement in gross margins with more favourable U.S. tariffs and as we shift from small scale batch production to continuous production with our contract manufacturers. In addition, we are not only focused on meeting accelerating U.S. sales growth, but also look to commercialize TerraSanteTM in new countries where there exists a need and potential for fast tracked registrations."Notes:
1) Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company's results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.About MustGrowMustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSanteTM, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 110 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 63.0 million common shares issued and outstanding, and approximately 76.7 million shares on a fully diluted basis.For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about:, the future demand for the Company's products, future sales and margins from those sales, and the impact of any tariffs,and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2025 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.© 2026 MustGrow Biologics Corp. All rights reserved.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294798
Original: MustGrow Announces 2025 Financial Results

MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility ProductApril 28, 2026 7:00 AM
NewsfileMustGrow has received approval from the Georgia Department of Agriculture to commence sales of TerraSante™, an organic biofertility product, in the State of Georgia.Mustard-derived TerraSante™ has been shown to improve crop yields, soil and soil microbiome health, and nutrient/water use efficiencies.Saskatoon, Saskatchewan--(Newsfile Corp. - April 28, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce receipt of the Georgia Department of Agriculture registration approval for its mustard plant-based TerraSante™, an organic biofertility product. The Georgia organic certification is included under MustGrow's existing Organic OMRI Listed® certifications in Florida, Arizona, Idaho, Oregon, and Washington State. MustGrow's Georgia registration and organic certification strengthens commercial opportunities as both Florida and Georgia's high-value crop acres are a natural fit for the success TerraSante™ is currently delivering in California. MustGrow's TerraSante™ is already approved for sale in Florida. TerraSante™ demand is growing in registered states along the West Coast of the U.S..In 2023, Georgia ranked #1 versus other U.S. states in peanuts production ($762 million USD cash receipts), #2 in pecans ($184 million USD cash receipts), and #3 in blueberries ($156 million USD cash receipts), which may or may not have a direct impact on MustGrow and its business.(1)TerraSanteTM for Soil and Ecological HealthMustGrow's mustard-derived TerraSante™ organic biofertilizer is a wettable powder containing nutritious plant proteins and carbohydrates that feed the soil and soil microbes, potentially improving beneficial microbial activity and long-term sustainable soil health. TerraSante™ is currently registered and approved for sale in California, Florida, Georgia, Arizona, Idaho, Oregon, and Washington State, under Organic OMRI Listed® certification and California's Organic Input Material (OIM) Program.MustGrow's biofertility program focuses on soil and soil microbiome health, nutrient and water use efficiencies, and plant yields. Soil is a farmer's most valuable asset, and MustGrow's mustard plant-based technologies are being applied with the intention to improve the health of the soil and soil microbiome, and have a positive impact on root and plant health. These targeted micro-communities have been shown to work to improve nutrient availability, which can potentially increase plant vigor and yields, while reducing plant stress. TerraSante™ has the potential to improve crop nutrient uptake and, hence, overall crop performance. There are no artificial additives or preservatives used during its manufacturing.To learn more about TerraSante™, visit TerraSante™ - MustGrow.Sources:1) GA Agricultural Facts - October 2024About MustGrowMustGrow Biologics Corp. is a provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's technology is centered on harnessing the natural defense mechanisms and organic compounds found in mustard seed and formulating them into organic biofertility, biostimulant, and biocontrol products. These solutions are designed to protect soil health and the soil microbiome, support plant health, and contribute to global food security through more sustainable agricultural practices. In the United States, MustGrow's flagship biofertility product, TerraSante™, is registered, organically certified, and commercially sold in key agricultural states, including California. Outside of North America, MustGrow is focused on collaborating with leading global agriculture companies, such as Bayer AG in Europe, the Middle East, and Africa, to commercialize its wholly owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio, which includes approximately 110 issued and pending patents. MustGrow is publicly traded on the TSX Venture Exchange under the symbol MGRO and has approximately 63.0 million common shares issued and outstanding, and approximately 76.7 million shares on a fully diluted basis.For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about: the Company's products, its potential impact on the Company, crop yields and soli health and the future expansion plans of the Company , and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: reliance of government approvals for certain products and those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.© 2026 MustGrow Biologics Corp. All rights reserved.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294507
Original: MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product

MustGrow's Canola Field Trials Demonstrate Clubroot Disease Suppression; Improved Canola Yield with Healthier Root SystemsFebruary 3, 2026 10:37 AM
NewsfileMustGrow's mustard-derived organic biocontrol technology TerraMGTM focuses on soil-borne disease and pest suppression, which has been shown to improve soil conditions, crop yields, and healthier root systems;Clubroot is a soil-borne parasitic disease with devastating effects on canola production across the Canadian Prairies with no effective products currently registered for Clubroot suppression;Field trial findings support TerraMGTM's role as a sustainable product capable of suppressing Clubroot and promoting higher canola yields and root systems under various disease pressures;MustGrow (via NexusBioAg) trialed approx. 100 acres over 2-year field program.Saskatoon, Saskatchewan--(Newsfile Corp. - February 3, 2026) -  MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce completion and results of its 2-year field trial program in the Canadian Prairies on approximately 100 acres of canola production. Field trial findings have demonstrated MustGrow's TerraMGTM is a sustainable technology capable of suppressing clubroot parasitic disease (P. brassicae) ("Clubroot") and promoting higher canola yields and root systems under various disease pressures.Clubroot is a soil-borne parasitic disease that has had devastating effects on canola production across the Canadian Prairies with no effective products currently available for Clubroot suppression. Canola is Canada's most valuable field crop, with 2025 production reaching approximately $14 billion (21.8 million tonnes at approximately $650/tonne)(1) and generating billions in annual export revenue. Without adequate treatment and management solutions, Clubroot continues to create major problems for Canadian canola farmers who need a solution. TerraMGTM: MustGrow's Answer to Clubroot MustGrow is actively working towards registering its organic biocontrol product TerraMGTM through Health Canada's Pest Management Regulatory Agency. TerraMGTM combats Clubroot through its mechanism, releasing naturally occurring isothiocyanates from mustard seed meal. Isothiocyanates are known to possess fungicidal and biocidal activity, suppressing a range of soil-borne pathogens, including Clubroot.In MustGrow's 2024 and 2025 field trials, conducted through its wholly-owned Canadian marketing and distribution business NexusBioAg, TerraMGTM-treated plots showed a significant reduction in resting spore concentrations of Clubroot relative to untreated controls. Visual assessments of canola root galls indicated reduced severity and incidence in treated plots. These findings support TerraMGTM's role as a sustainable biocontrol capable of suppressing Clubroot inoculum and promoting higher canola yields and healthier root systems under various disease pressure.In 2024, Clubroot spores were more prevalent due to a wetter growing season, and TerraMGTM performed exceptionally well with up to 95% reductions in Clubroot spores. Disease pressure was consistent throughout the season due to the wetter conditions. Yield benefits to the grower showed up to a 7 bushel/acre increase (19% increase over Canada's 36 bushel/acre average production in 2024)(2), translating to a $91/acre increase in value to the farmer (at approximately $13/bushel average commodity price)(3).In 2025, according to internal data, canola farmers experienced a relatively dry season and correspondingly less Clubroot disease prevalence than the much wetter 2024 season. Yield increase utilizing TerraMGTM demonstrated a 1-2 bushel/acre increase over the control, which was less impactful than 2024, with less Clubroot infestation in the fields to address.Detrimental Disease with Limited Options for FarmersThe 15-20 year longevity of Clubroot's highly resilient resting spores is a key element of Clubroot's persistence and detrimental impact on canola. The parasitic disease induces gall formation on roots, disrupting water and nutrient uptake. Early infection with moderate to high spore loads can lead to 100% loss of canola crop. Infection at the early seedling stage can later result in wilting, stunting, yellowing and death of canola plants. In later crop stages, inflection may not necessarily show wilting, stunting or yellowing, but infected plants may ripen prematurely, resulting in shriveled seeds and negatively impacting yield, oil content, and quality.(4)No effective products are currently registered for Clubroot suppression in canola. Current farming practices include extensive sanitation and equipment cleaning, long crop rotations (3-4 years between canola crops), and genetically-modified resistant canola varieties. While genetic resistance in commercial canola hybrids initially provided strong control, new mutated Clubroot pathotypes are now capable of overcoming resistance.(4)These methods, while partially effective, are economically and logistically challenging. A biological, soil-active technology, like MustGrow's TerraMGTM, capable of reducing resting spore loads could represent a significant breakthrough in sustainable Clubroot management for Canadian farmers.References:1) Production of principal field crops, November 2025
2) Production of principal field crops, November 2024
3) Feed Grain - Other Crops - Canola Prices 2024.xlsx
4) Clubroot Disease | Canola EncyclopediaAbout MustGrowMustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow's wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow's wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 110 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV: MGRO) and has approximately 62.9 million common shares issued and outstanding and 77.0 million shares fully diluted. For further details, please visit www.mustgrow.ca.Contact InformationCorey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.caMustGrow Forward-Looking StatementsCertain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements in this news release, including statements about: the impact and significance of customer performance data and field testing, the increase in value of yields and the costs of such increase in value, if any, and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.© 2026 MustGrow Biologics Corp. All rights reserved.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282525
Original: MustGrow's Canola Field Trials Demonstrate Clubroot Disease Suppression; Improved Canola Yield with Healthier Root Systems

What's Up Vulcan you're the OG on this board. It is recognized and appreciated. I've been following this company for years now, about to throw in more on it. Was such a small float this could go to 20 quite easily A few contracts

Feb 6, 2024 | News Releases

MustGrow Receives Registration Approval for TerraSante™ in Oregon MustGrow has received The State of Oregon Agriculture approval to commence sales of TerraSanteTM, an organic biofertility product, in Oregon. MustGrow’s recently-awarded organic compliance certification...

Hit u up for #135. Looks like time to add a few. Best of luck.

Nothing like catching a second wind!

looks like we are late to the after party, but early to the renaissance.

getting close for an entry. been watching this one. fantastic product that will only see an increase in demand as agricultural increases without harsh cancer causing chemicals will be needed more than ever.

Adding more this morning. Cant believe it. Up another 15% right out of the gate.

Spock.....highly illogical!

MGROF.....the gift that keeps on giving .

Up a dollar per share i just a couple of months. Smokin'!!

Spock.....how are so many people missing out on this!!

Well, i've gotten decent appreciation on this since August, yet i am still the only obne posting here. 10:1 Buy/Sell ratio today. Things are going very well here. I wish others would come to help share this good deal.

Spock.......it's lonely out in space.

Well, i've gotten decent appreciation on this since August, yet i am still the only obne posting here. 10:1 Buy/Sell ratio today. Things are going very well here. I wish others would come to help share this good deal.

Spock.......it's lonely out in space.

The stock has appreciated nicely over the past few months and their cash on hand:debt ratio is...


9.8 :1 CAN.

it just keeps getting better. RIGHT NOW this is looking like a very decent buy and hold at least.

Spock.... I love living in space. Oh, hey, it's almost time for happy hour.

7:1 Buys to Sells so far this morning, 8/12/21. Price holding very well. RSI is a bit hot and needs to cool off a bit.

This is, as far as I can see, a quality company with a quality ranking and a great SS.

S.

Yesterday, Aug.11 saw some really nice appreciation. 25%.

My DD work flushes out that Mustgrow Is a young company with very good product. I thought to myself, why should this stock go up much more this year? The growing season only has maybe 8 weeks left in it in North America.

Then I learned that the product works all over the world where there is always a growing season. Further, a cheap product that is good for many crops and returns much improved plants is something any help, cannabis or other crop wants all the time.

As this company grows we should see so wonderful times here. Their share structure is so solid they put it in the home page of their website. GOTTA LOVE THAT.

More later, Spock.

Welcome. As of this moment, I have not yet even completed what any good investor might call quality "DD", but as I work on it I'm up about 11% in a week here.

What has me excited is the partnership they have established with SSUMY in Tokyo. That is a huge conglomerate. Both companies are Pink/Current . And both are doing pretty well.

Join me as I learn about this company and assess its potential.

Spock....aka ....jon-michael.